<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>
	Comments on: Update on liraglutide (Novo Nordisk’s Victoza)—approved by the FDA for treatment of type 2 diabetes	</title>
	<atom:link href="https://biopharmconsortium.com/2010/01/29/update-on-liraglutide-novo-nordisks-victoza-approved-by-the-fda-for-treatment-of-type-2-diabetes/feed/" rel="self" type="application/rss+xml" />
	<link>https://biopharmconsortium.com/2010/01/29/update-on-liraglutide-novo-nordisks-victoza-approved-by-the-fda-for-treatment-of-type-2-diabetes/#utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=update-on-liraglutide-novo-nordisks-victoza-approved-by-the-fda-for-treatment-of-type-2-diabetes</link>
	<description>Consulting for Effective Life R &#38; D and Partnering</description>
	<lastBuildDate>Fri, 29 Jan 2010 00:00:00 +0000</lastBuildDate>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>
</channel>
</rss>
